Hedenström, Per http://orcid.org/0000-0002-4106-1454
Andersson, Carola
Sjövall, Henrik
Enlund, Fredrik
Nilsson, Ola
Nilsson, Bengt
Sadik, Riadh
Funding for this research was provided by:
Sahlgrenska University Hospital (LUA-ALF 73830, LUA-ALF 70150)
Stiftelsen Assar Gabrielssons Fond (FB17-20)
The health and Medical Care committee of the Regional Executive Board, Region Västra Götaland (VGFOUREG-564381, VGFOUREG-665681)
Magtarmfonden (A79211)
Article History
First Online: 2 March 2020
Compliance with Ethical Standards
:
: This work was not supported by any commercial or financial interests. Research grants were obtained from the following noncommercial foundations: The Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland (Grant number: VGFOUREG-564381 and VGFOUREG-144591); Sahlgrenska University Hospital (LUA-ALF, Grant number: 73830, 74370, and 70150); The Assar Gabrielsson Foundation (Grant number: 17-20); and Magtarmfonden (Grant number: 79211).
: Per Hedenström, Carola Andersson, Henrik Sjövall, Ola Nilsson, Bengt Nilsson, and Riadh Sadik declare they have no conflicts to report. Fredrik Enlund reports lecture honorarium from Novartis, Astra Zeneca, Roche, Lilly, and Astellas.
: This study was approved by the Regional Ethical Review Board of Gothenburg. Written informed consent was obtained from all the study participants. The study was registered at ClinicalTrials.gov (NCT02360839).